Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory legal settlement

Bayer Monsanto $7.25B Roundup Settlement Hearing

Analysis based on 10 articles · First reported Sep 11, 2026 · Last updated Sep 11, 2026

Sentiment
15
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Approval of the $7.25 billion settlement would remove a major legal overhang that has weighed on Bayer's share price since the 2018 Bayer — Monsanto acquisition, potentially unlocking value if it caps future Roundup liabilities. A rejection or prolonged litigation would revive uncertainty over Bayer's balance sheet and could pressure the stock, while also affecting sentiment toward glyphosate-dependent agricultural chemical peers.

agriculture chemicals pharmaceuticals

Bayer's Bayer — Monsanto unit appeared before the Missouri Circuit Court in St. Louis on September 14, 2026, seeking final approval of a $7.25 billion class settlement intended to resolve tens of thousands of U.S. lawsuits alleging that the Roundup weedkiller causes non-Hodgkin lymphoma. Judge Timothy Boyer examined the terms of the deal and heard objections from plaintiffs' attorneys who argue the settlement pushes claimants into a framework against their interests, as well as from lawyers who say it is the best route to compensation. Boyer is not expected to issue an immediate ruling. Bayer announced the proposed settlement in February 2026; it would cover roughly 65,000 claims in U.S. state and federal courts, with individual payouts ranging from $10,000 to $165,000 depending on disease severity, age at diagnosis, and exposure setting. The hearing followed the Eighth Circuit Court of Appeals' August 27 dismissal of objectors' attempt to move the settlement decision to federal court and Judge Boyer's rescheduling of the hearing to September 14 after a joint motion by Bayer — Monsanto and class counsel. The litigation dates to a 2015 determination by the World Health Organization's International — International Agency for Research on Cancer that glyphosate was a probable carcinogen, while the U.S. Environmental Protection Agency has consistently found glyphosate not likely to cause cancer and is working on an updated human health risk assessment expected in late 2026. In June 2026 the United States — Supreme Court of the United States ruled 7-2 that the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims where the EPA has made a definitive safety determination, undercutting a central legal theory in thousands of pending cases. Bayer denies the allegations and says decades of studies show glyphosate is safe. The litigation has been a major overhang on Bayer since its 2018 acquisition of Bayer — Monsanto, and investors view the settlement as a key test of Chief Executive Bill Anderson's turnaround plan.

90 Bayer announced settlement
85 Bayer — Monsanto filed settlement
55 Bayer settled Roundup lawsuits
45 Timothy Boyer rescheduled approval hearing
stock
Bayer is the central party seeking court approval of the $7.25 billion settlement to resolve roughly 65,000 Roundup claims; approval would remove a major legal overhang and support its turnaround, while rejection would prolong litigation and weigh on its shares.
Importance 100.0 Sentiment 25.0
subs
Bayer — Monsanto, Bayer's subsidiary, is the defendant in the Roundup litigation and the entity whose settlement is before the court; it maintains the class settlement is fair and warrants final approval.
Importance 90.0 Sentiment 20.0
per
Judge Timothy Boyer of the Missouri Circuit Court is presiding over the final approval hearing, weighing objections and the settlement terms; his eventual ruling will determine whether the deal proceeds.
Importance 60.0 Sentiment 0.0
per
As Bayer's Chief Executive, Bill Anderson's turnaround plan is seen as hinging on resolving the Roundup claims, making the settlement hearing a key test of his leadership.
Importance 40.0 Sentiment 10.0
govactor
The Supreme Court's June 2026 7-2 ruling for Bayer — Monsanto on federal preemption of failure-to-warn claims undercut a central legal theory in thousands of Roundup cases, strengthening Bayer's position.
Importance 35.0 Sentiment 0.0
govactor
The EPA's finding that glyphosate is not likely to cause cancer and its pending updated risk assessment are central to the legal debate over Roundup warning labels.
Importance 30.0 Sentiment 0.0
govactor
The agency's 2015 determination that glyphosate was a probable carcinogen gave momentum to the Roundup lawsuits that Bayer is now trying to settle.
Importance 25.0 Sentiment 0.0
ngo
The World Health Organization is referenced through its cancer research arm's 2015 glyphosate classification, which helped spark the Roundup litigation.
Importance 20.0 Sentiment 0.0
govactor
The Eighth Circuit dismissed objectors' attempt to move the settlement decision to federal court on August 27, keeping the matter before Judge Boyer in Missouri state court.
Importance 20.0 Sentiment 0.0
cnt
The United States is the jurisdiction hosting the roughly 65,000 Roundup claims and the state and federal courts where the litigation and settlement approval are proceeding.
Importance 15.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.